{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009567","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.842917+00:00","generated_at":"2026-06-01T00:23:15.103683+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Stockholders approve increase in share reserve for 2006 Stock Incentive Plan to 17.5M shares","bullets":["Seven directors elected; CEO Dror Bashan among those with over 22M for votes.","Advisory vote on executive compensation passed: 17.0M for, 9.88M against.","Stock plan amended: shares available increased from ~12.5M to 17,475,171.","Kesselman & Kesselman (PwC Israel) ratified as auditor for fiscal 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009567","json":"https://secwatch.observer/filing/0001558370-24-009567.json","markdown":"https://secwatch.observer/filing/0001558370-24-009567.md","text":"https://secwatch.observer/filing/0001558370-24-009567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/0001558370-24-009567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/plx-20240627x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:23:15.103683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}